0000899243-20-029830.txt : 20201029 0000899243-20-029830.hdr.sgml : 20201029 20201029214222 ACCESSION NUMBER: 0000899243-20-029830 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201019 FILED AS OF DATE: 20201029 DATE AS OF CHANGE: 20201029 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Endo International plc CENTRAL INDEX KEY: 0001593034 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 201274519 BUSINESS ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 353-1-268-2000 MAIL ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER NAME: FORMER CONFORMED NAME: Endo International Ltd DATE OF NAME CHANGE: 20131203 FORMER NAME: FORMER CONFORMED NAME: Sportwell Ltd DATE OF NAME CHANGE: 20131126 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 302-842-8450 MAIL ADDRESS: STREET 1: 2 RIGHTER PARKWAY, SUITE 200 CITY: WILMINGTON STATE: DE ZIP: 19803 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-10-19 0 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001593034 Endo International plc FIRST FLOOR, MINERVA HOUSE, SIMMONSCOURT ROAD BALLSBRIDGE, DUBLIN 4 L2 IRELAND 0 0 0 1 See footnotes (1)(2)(3)(4) Common Stock, $0.001 par value 0 I See footnotes The Reporting Persons do not beneficially own any equity securities of BioSpecifics Technologies Corp. (the "Issuer") as defined in Rule 16a-1(a)(2) of the Exchange Act. The Reporting Persons are filing this Form 3 solely due to the entry into a Support Agreement, dated as of October 19, 2020 (the "Support Agreement"), by and among the Reporting Persons and the Marital Trust U/W/O Edwin H. Wegman dated 8-10-06 (the "Stockholder"), representing an aggregate of 935,073 shares of the Issuer's common stock beneficially owned by the Stockholder, which represents approximately 12.7% of Issuer's total outstanding shares based on 7,344,955 shares of the Issuer's common stock (consisting of 7,344,955 shares of the Issuer's common stock reported outstanding as of October 19, 2020). The Support Agreement was entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 19, 2020, by and among the Reporting Persons and the Issuer. For additional information regarding the Support Agreement and the Merger Agreement, see Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission on October 29, 2020. Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3. Generally, upon the exercise of any security convertible or exchangeable for any Issuer common stock by the Stockholder party to the Support Agreement, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreement and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreement. No securities beneficially owned. /s/ Matthew J. Maletta, as Executive Vice President, Chief Legal Officer and Company Secretary on behalf of Endo International plc 2020-10-29